|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"shan ys"
Showing items 111-133 of 133 (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Siveke, JT;Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Braiteh, F;Moyo, V;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy
|
Chiang, NJ;Yeh, KH;Chiu, CF;Chen, JS;Yen, CC;Lee, KD;Lin, YL;Bai, LY;Chen, MH;Lin, JS;Yang, Y;Rau, KM;Hsiao, HH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC)
|
Chiang, NJ;Tsai, KK;Chen, JS;Yang, SH;Hsu, C;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-01 |
Investigating the association between periodontal disease and risk of pancreatic cancer
|
Chang, JS;Tsai, CR;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial
|
Chen, MH;Lin, J;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-10 |
Epigenetic regulation in the carcinogenesis of cholangiocarcinoma
|
Chiang, NJ;Shan, YS;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan
|
Chou, WC;Liu, CT;Chen, MH;Lu, CH;Ku, FC;Su, YL;Shan, YS;Chen, LT;Chen, YY;Chen, JS |
| 國家衛生研究院 |
2015-08 |
The association between periodontal disease and pancreatic cancer
|
Chang, JS;Tsai, CR;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2015-06 |
Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Lin, SF;Hsiao, SY;Tsai, CR;Yu, SJ;Tsai, HJ |
| 國家衛生研究院 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Chao, Y;Shan, YS;Huang, SF;Chiu, CF;Lee, KD;Chen, LT |
| 國家衛生研究院 |
2013-11 |
A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression
|
Wang, WY;Hsu, CC;Wang, TY;Li, CR;Hou, YC;Chu, JM;Lee, CT;Liu, MS;Su, JJ;Jian, KY;Huang, SS;Jiang, SS;Shan, YS;Lin, PW;Shen, YY;Lee, MT;Chan, TS;Chang, CC;Chen, CH;Chang, IS;Lee, YL;Chen, LT;Tsai, KK |
| 國家衛生研究院 |
2013-11 |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen, L;Shan, YS;Hu, HM;Price, TJ;Sirohi, B;Yeh, KH;Yang, YH;Sano, T;Yang, HK;Zhang, X;Park, SR;Fujii, M;Kang, YK;Chen, LT |
| 國家衛生研究院 |
2013-08 |
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
|
Ko, AH;Tempero, MA;Shan, YS;Su, WC;Lin, YL;Dito, E;Ong, A;Wang, YW;Yeh, CG;Chen, LT |
| 國家衛生研究院 |
2013-06-20 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations
|
Hsueh, YS;Lin, CL;Chiang, NJ;Yen, CC;Li, CF;Shan, YS;Ko, CH;Shih, NY;Wang, LM;Chen, TS;Chen, LT |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2012-08 |
Krüppel-like factor 10 expression as a prognostic indicator for pancreatic adenocarcinoma
|
Chang, VHS;Chu, PY;Peng, SL;Mao, TL;Shan, YS;Hsu, CF;Lin, CY;Tsai, KKC;Yu, WCY;Ch'ang, HJ |
| 臺北醫學大學 |
2012 |
Kr?ppel-Like Factor 10 Expression as a Prognostic Indicator for Pancreatic Adenocarcinoma
|
VHS, Chang;Chu, PY;Peng, SL;Mao, TL;Shan, YS;Hsu, CF;Lin, CY;KKC, Tsai;WCY, Yu;Ch'ang, HJ |
| 國家衛生研究院 |
2011-12 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study
|
Ch'ang, HJ;Lin, YL;Wang, HP;Chiu, YF;Chang, MC;Hsu, CH;Tien, YW;Chen, JS;Hsieh, RK;Lin, PW;Shan, YS;Cheng, AL;Chang, JY;Whang-Peng, J;Hwang, TL;Chen, LT |
Showing items 111-133 of 133 (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page
|
